Revenue
2014
2016
2020
2021
2022
2023
2024
2026
Protagenic Therapeutics, Inc.\new (PTIX)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2026
Free cash flow
2014
2015
2022
2023
2026
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2026
Financial statements
| 2026 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | — | — | — | $0 | — | $0 |
| Research & development | $901,896 | $3.8M | $3.1M | $1.6M | $1.1M | $699,797 | $807,947 | $881,186 | $717,452 | $417,866 | — | $42,000 |
| Operating expenses | $4.5M | $5.7M | $4.5M | $3.6M | $4.1M | $2.6M | $2.1M | $2.3M | $2.4M | $2.2M | $491,000 | $975,000 |
| Operating income | −$4.5M | −$5.7M | −$4.5M | −$3.6M | −$4.1M | −$2.6M | −$2.1M | −$2.3M | −$2.4M | −$2.2M | −$491,000 | −$975,000 |
| Net income | $1.4M | −$5.5M | −$5.0M | −$3.6M | −$4.5M | −$2.5M | −$1.8M | −$2.6M | −$2.3M | −$2.3M | −$476,000 | −$1.1M |
| Basic EPSper diluted share | $0.59 | -$1.13 | -$1.15 | -$0.82 | -$1.24 | -$0.25 | -$0.17 | -$0.25 | -$0.22 | -$0.43 | $0.00 | $0.00 |
| Diluted EPSper diluted share | $0.59 | -$1.13 | -$1.15 | -$0.82 | -$0.31 | -$0.25 | -$0.17 | -$0.25 | -$0.22 | -$0.43 | $0.00 | $0.00 |